Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy
We report 2 cases of intravenous immunoglobulin refractory ITP in children receiving chemotherapy for high-risk neuroblastoma. ITP was successfully treated with the thrombopoietin-receptor-agonist romiplostim, allowing safe and timely continuation of antineuroblastoma therapies in these high-risk patients.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Children | Hematology | Laboratory Medicine | Neuroblastoma | Neurology | Pediatrics | Thrombocytopenia